Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
- 1 June 2020
- journal article
- review article
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 41 (2) , 223-235
Abstract
No abstract availableKeywords
Funding Information
- BeyondSpring Pharmaceuticals
This publication has 114 references indexed in Scilit:
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesJournal of Clinical Oncology, 2013
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Annals of Oncology, 2013
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Targeting Anaplastic Lymphoma Kinase in Lung CancerClinical Cancer Research, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- The biology and treatment of EML4-ALK non-small cell lung cancerEuropean Journal of Cancer, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progressionOncogene, 2004
- Mutations of the BRAF gene in human cancerNature, 2002